Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
14 nov. 2017 16h05 HE | aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
Atyr_Logo.png
aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
27 sept. 2017 08h00 HE | aTyr Pharma Inc.
SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
14 août 2017 16h05 HE | aTyr Pharma Inc.
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
Atyr_Logo.png
aTyr Pharma Announces First Quarter 2017 Operating Results
11 mai 2017 16h05 HE | aTyr Pharma Inc.
 – Announced Promising Top-Line Results from ResolarisTM  Phase 1b/2 Trial in Early Onset FSHD –– Preclinical Data from StalarisTM Program to be Presented at American Thoracic Society...
Atyr_Logo.png
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
24 avr. 2017 08h00 HE | aTyr Pharma Inc.
- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...